Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Februar 2026 07:35 ET | Quelle: Jeito Capital

Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million

Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved...
24. Februar 2026 07:30 ET | Quelle: Alveus Therapeutics Inc

Alveus Therapeutics Announces Second and Final Closing of Oversubscribed Series A, Bringing Total Financing to $197 Million to Advance Next‑Generation Therapies for Obesity and Metabolic Diseases

Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega FundsAdditional capital further supports clinical...
24. März 2025 02:10 ET | Quelle: Jeito Capital

Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases

Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases Proceeds from...
12. November 2024 07:10 ET | Quelle: Jeito Capital

Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors

Jeito Capital co-leads €164.5 million1 ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development ofAnti-Claudin-1 (CLDN1) ADCs in solid tumors ...